Abstracts

TRANSMITTED DRUG RESISTANCE IN PEOPLE LIVING WITH DIAGNOSED HIV IN CALIFORNIA

Increased antiretroviral use for treatment and prevention raises concern that rates of transmitted drug resistance may increase. We analyzed a population-based dataset of HIV-1 pol sequences to estimate the prevalence of transmitted drug resistance-associated mutations (DRAMs) in people living with HIV in California from 2008-2018 and evaluated the transmission potential of identified mutations. HIV-1 pol…

ADVANCE TRIAL: HIGHER RISK OF TREATMENT-EMERGENT RESISTANCE ON FIRST-LINE TDF/FTC/EFV

In low- and middle-income countries, most treatment-naïve people living with HIV (PLWH) take first-line treatment with no baseline resistance testing.  In the SINGLE trial, there was a significantly higher risk of treatment-emergent drug resistance in the TDF/FTC/EFV arm (1.7%) compared with the ABC/3TC/DTG arm (0.0%).  In South Africa, over 10% of treatment-naïve patients have transmitted…

A HIGHLY POTENT AND SAFE ALLOSTERIC HIV-1 INTEGRASE INHIBITOR, STP0404

Allosteric HIV-1 integrase inhibitors (ALLINIs) are a new class of HIV-1 inhibitors, targeting HIV-1 maturation process. While great efforts have been made for the discovery of ALLINIs, clinical development of ALLINIs has not been successful mainly due to their preclinical limitations. We recently discovered a highly potent and safe IN inhibitor STP0404 with outstanding antiviral…

PHASE II TRIAL OF VPU INHIBITOR BIT225 IN COMBINATION WITH ANTIRETROVIRAL THERAPY

Vpu is a HIV-1 encoded membrane protein with multiple regulatory functions that enhance HIV-1 replication fitness and promote innate immune evasion in multiple cell types including monocytes. BIT225 inhibits HIV-1 replication in myeloid cells in vitro. BIT225 has been studied in patients with chronic HIV-1 infection receiving antiretroviral therapy (ART). A randomized, placebo controlled, double-blind, Phase…

CLINICAL SIGNIFICANCE OF gp120 POLYMORPHISMS, TMR IC50FC AND HIV-1 SUBTYPE IN BRIGHTE

The ongoing Ph3 BRIGHTE study is evaluating Fostemsavir (FTR), an investigational prodrug of the first-in-class attachment inhibitor temsavir (TMR), in heavily treatment-experienced (HTE) participants with multi-drug resistant HIV-1 infection who are unable to form a viable regimen from fully active ARV agents. We present the impact of key baseline (BL) factors on short-term virologic outcome…

COMPARABLE EFFICACY OF IBALIZUMAB IN COMBINATION WITH 1 OR 2 FULLY ACTIVE AGENTS

Current guidelines recommend a regimen containing at least two, preferably three, fully active agents to suppress viremia in HIV treatment-experienced patients. However, identifying three fully active agents presents a challenge for some multidrug resistant (MDR) HIV patients. Ibalizumab (IBA), a CD4-directed post-attachment HIV-1 inhibitor, is approved for MDR patients failing their ART regimen. We sought to…